Top news of the week: 29.09.2020.
Biotechnology, Clinical trial, Finance, Effectiveness, Estrogen receptor, Health care
Startups
Here come the tortoises: In the race for a Covid-19 vaccine, slow starters could still win out https://t.co/ANM3IpNljC via @HelenBranswell $SNY $MRK
OpenHere come the tortoises: In the race for a Covid-19 vaccine, slow starters could still win out
Anyone handicapping the so-called competition to develop vaccines would do well to keep an eye on the players who seemingly got a late start.
4th time's the charm: Longitude Capital raises $585M in its largest-ever fund https://t.co/dSliHxPd17 https://t.co/fmV0FJDZKZ
Open4th time's the charm: Longitude Capital raises $585M in its largest-ever fund
The co-founders and co-managing directors of Menlo Park, Greenwich Village and Boston-based healthcare venture capital firm Longitude Capital invest in areas they hope will increase life ...
Medicxi raises €200M to take 6 biotechs deeper into the clinic https://t.co/HASTVVil5P https://t.co/gedJbRT6Mk
OpenMedicxi raises €200M to take 6 biotechs deeper into the clinic
Medicxi has secured €200 million ($235 million) to support six companies. The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index ...
It's also targeting COVID-19 using its oligonucleotide approaches, aiming for “pan-coronavirus” activity. https://t.co/iZJAHWckqK
OpenHep B player Aligos Therapeutics wants to go public with a $100M IPO, COVID-19 drug plans
Oligonucleotide-focused biotech Aligos Therapeutics is shooting for a $100 million IPO to help drive its early work on a functional cure for chronic hepatitis B as well as COVID-19.
Welcome to GV. Monte Rosa Therapeutics develops precision medicines to degrade disease-causing proteins – https://t.co/2yoSTiwWjk
OpenVersant's Monte Rosa reels in $96M to bankroll 'molecular glue' treatments for cancer, other diseases
Creating drugs that harness the body’s protein-degrading processes is not a new idea; companies like Arvinas are using this approach to destroy disease-causing proteins rather than simply ...
This Startup Has Raised Nearly $100 Million To Make Good On The Promise Of AI For Drug Discovery
Flagship Pioneering’s David Berry founded Valo Health 18 months ago with an eye to making an AI platform to develop drugs more quickly and efficiently.
A covid-19 vaccine developed by Johnson & Johnson & Boston's Beth Israel Deaconess Medical Center @BIDMChealth will start undergoing testing on volunteers in a large study (up to 60,000 volunteers) today. 1st covid vaccine in Ph3 w/one shot instead of two https://t.co/MJGWrnQDES
OpenMajor study to start for COVID-19 vaccine developed by Johnson & Johnson, Beth Israel
Up to 60,000 volunteers, including some in Boston, will take part in the trial following encouraging data from more limited testing.
South Korean exosome biotech Ilias Biologics nabs $20M B round https://t.co/wd0Ld3u5eb https://t.co/sV9jlsF2qv
OpenSouth Korean exosome biotech Ilias Biologics nabs $20M B round
Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading candidate ILB-202.